Table 1.
Clinical characteristics of patients and (disease) controls used for plasmas.
| Patient Code | Gender | Sample Code | Age at Sampling Time | PP Session Number |
PP-Responsive
Yes/No |
Kidney Transplant Number |
Onset of
Recurrence after TX |
| rec1 | M | rec1A *,# | 73 | 1 | yes | pre-TX | NA |
| rec1B * | 74 | 1 | yes | 1 | Day 3 | ||
| rec1C | 74 | 4 | yes | 1 | |||
| rec2 | M | rec2A *,# | 61 | 1 | no | pre-TX | Day 2 |
| rec2B * | 61 | 5 | no | pre-TX | |||
| rec3 | M | rec3A * | 21 | 1 | no | pre-TX | NA |
| rec3B *,# | 21 | 10 | no | pre-TX | NA | ||
| rec3C * | 24 | 1 | yes | 1 | Day 3 | ||
| rec3D | 24 | 9 | yes | 1 | |||
| rec3E * | 24 | 1 | yes | 1 | Day 29 | ||
| rec3F | 24 | 4 | yes | 1 | |||
| rec4 | M | rec4 * | 20 | 1 | no | 1 | Day 2 |
| rec5 | M | rec5 * | 26 | 1 | no | 1 | Day 2 |
| rec6 | F | rec6 * | 40 | 1 | yes | 1 | 2 months |
| rec7 | F | rec7 * | 32 | 1 | yes | 3 | Day 1 |
| rec8 | F | rec8 * | 39 | 1 | yes | 1 | Day 1 |
| nat1 | M | nat1A *,# | 18 | 1 | yes | NA | NA |
| nat1B | 21 | Maintenance PP | yes | NA | NA | ||
| healthy | 3F, 2unk | healthy | unk | no PP | NA | NA | NA |
| IgA | F | IgA | 66 | 1 | NA | NA | NA |
| nonrec1 | M | nonrec1 | 68 | no PP | NA | 1 | NA |
| nonrec2 | M | nonrec2 | 27 | no PP | NA | 1 | NA |
| Patient Code | Gender | Sample Code |
Serum creatinine
(µmol/L) |
Serum
albumin (g/L) |
Proteinuria
(g/10 mmol creatinine) |
Immunosuppression at Sampling Time | |
| rec1 | M | rec1A *,# | 742 | 22 | 7.5 | None (pre-TX sample) | |
| rec1B * | 169 | 28 | 4.0 | Tacro, MMF, Pred | |||
| rec1C | 168 | 31 | 1.5 | Tacro, MMF, Pred | |||
| rec2 | M | rec2A *,# | 200 | 18 | 11.8 | Pred | |
| rec2B * | 203 | 24 | 11.4 | Pred | |||
| rec3 | M | rec3A * | 165 | 10 | 11.8 | Pred | |
| rec3B *,# | 127 | 12 | 10.5 | Pred | |||
| rec3C * | 200 | 18 | 5.4 | Tacro, MMF, Pred | |||
| rec3D | 185 | 26 | 1.8 g/day | Tacro, MMF, Pred | |||
| rec3E * | 193 | 29 | 4.5 | Tacro, MMF, Pred, Rtx | |||
| rec3F | 193 | 32 | 1.4 | Tacro, MMF, Pred, Rtx | |||
| rec4 | M | rec4 * | 127 | 24 | 23.0 | Tacro, MMF, Pred | |
| rec5 | M | rec5 * | 271 | 29 | 9.5 | Bas pre-TX, Tacro, MMF, Pred | |
| rec6 | F | rec6 * | 184 | 40 | 11.6 | Tacro, MMF, Pred | |
| rec7 | F | rec7 * | 678 | 40 | 9.0 | Rtx pre-TX, Tacro, MMF, Pred | |
| rec8 | F | rec8 * | 146 | 27 | 20.0 | Tacro, MMF, Pred | |
| nat1 | M | nat1A *,# | 459 | 9 | 7.3 | Mpred | |
| nat1B | 74 | 34.4 | 2.3 | Mpred | |||
| healthy | 3F, 2unk | healthy | unk | unk | unk | None | |
| IgA | F | IgA | 574 | 26 | Oliguric | None | |
| nonrec1 | M | nonrec1 | 86 | 39 | <0.1 | Tacro, Pred | |
| nonrec2 | M | nonrec2 | 224 | 34 | 0.4 | Tacro, MMF, Pred | |
*: active disease FSGS sample with presumed CPF(s); #: plasma induced high granularity in hPod; Bas: Basiliximab; healthy: pooled plasma from five healthy donors; IgA: IgA nephropathy; MMF: Mycophenolate; Mpred: Methylprednisone; NA: not applicable; nat: patient with FSGS in the native kidneys; nonrec: non-recurrent FSGS (FSGS patient without post-transplant recurrence); PP: plasmapheresis (no PP: whole blood plasma); Pred: Prednisone; rec: patient with recurrence of FSGS after transplantation; Rtx: Rituximab; Tacro: Tacrolimus; TX: transplantation; unk: unknown.